AT148002 (ALX Oncology) Description: A Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome (MDS) Mechanism of Action: ALX148 is a CD47 blocker. Target Patient Population: High Risk MDS Study Design: Study Drug will be administered IV every 2 or 4 weeks. Combination drug, Azacitidine given as would
Clinical Trial Type: Other
ALPN-202-NEON-1 (Alpine Immune Sciences)
ALPN-202 – NEON-1 (Alpine Immune Sciences) Description: An open-Label Study of ALPN-202 In Subjects With Advanced Malignancies (NEON-1) Target Patient Population: Currently in expansion for Melanoma, Renal cell and PDL1 positive cancers only Study Design: Study drug is administered IV every 1 or 3 weeks
AstraZeneca (CAPITELLO-281)
A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by PTEN deficiency (CAPItello-281) Principal Investigator: Dr. Eric Batts For more information on this trial, read its profile on clinicaltrials.gov here.
AstraZeneca PANCAN
A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumours PI: Dr. Chandana Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion For more information on this
CPI-0209-01 (Constellation)
CPI-0209-01 (Constellation) Description: A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Solid Tumors Target Patient Population: In Phase 2 with slots for tumors with known ARID1A mutations in Lymphoma, Mesothelioma, Urothelial and Endometrial. Study Design: Drug is given orally daily.
GSK2857916 (DREAMM5) (GlaxoSmithKline Research)
GSK2857916 (DREAMM5) (GlaxoSmithKline Research) Description: As Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 Target Patient Population: Multiple Myeloma Study Design: Study Drug is administered IV every 3 weeks. Combination arms with
GCT1046-01 (Genmab)
GCT1046-01 (Genmab) Description: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors Target Patient Population: Currently in Expansion with the following target populations: NSCLC (PD-1/L1 pre-treated or naïve) Study Design: Study drug is given IV every 21 days.
GENMAB (GCT1046-04)
GENMAB (GCT1046-04) A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor PI: Dr. Chen Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at
Guardant Health 02-MX-003 (ORACLE)
INBRX-105 (InhibRx)
Description: An Open Label, Multicenter, First-in-Human, Dose-Escalation Phase 1 Study of INBRX-105 in Subjects with Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma Target Patient Population: PD-L1+ (CPS ≥ 5) Melanoma, NSCLC, Head and Neck Squamous cell Study Design: Drug is given IV every 3 weeks